Alivus Life (ALIVUS)

FairStock Score: 48/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Outstanding capital efficiency: ROE of 21.42% and ROCE of 24.92%
• Near-zero debt (D/E 0.02) provides financial stability and downside protection
• Strong promoter holding of 74.91% aligns management with minority shareholders
• Healthy Piotroski F-Score of 7/9 indicates solid fundamentals
• Profit growth of 23.35% significantly outpacing sales growth, showing operational leverage

Concerns

• Very low revenue growth of 4.84% – profit growth may not be sustainable without top-line expansion
• Rich valuation: P/B of 5.11 and PEG of 1.41, leaving little margin of safety
• Low dividend yield of 0.55%, so total return depends entirely on price appreciation
• FairStock Score of 44/100 suggests a mixed outlook, with potential overvaluation or weak growth signals

AI Analysis

When I look at Alivus Life, I see a business with many of the qualities I admire, but at a price that demands caution. The company earns a return on equity of 21.42% and a return on capital of 24.92% – numbers that would make any capital allocator take notice. Debt-to-equity is a mere 0.02, so this is a fortress balance sheet. Promoters hold 74.91%, aligning their interests with mine as a minority shareholder. The Piotroski score of 7/9 also confirms a healthy financial position. Yet, I must ask: what is the growth engine? Sales grew only 4.84%, while profits jumped 23.35%. That tells me the recent earnings surge is margin-driven, not volume-driven. Such expansion can be sustainable for a time, but it is not the same as top-line momentum. The P/E of 19.90 is reasonable for a high-ROE pharma, but the P/B of 5.11 means I am paying a steep premium to book value. The dividend yield is just 0.55%, so I am not being paid to wait. With a PEG of 1.41, the growth is not particularly cheap. This feels like a well-run, nimble pharma stalwart – a quality compounder with a wide moat, but one that needs to show me stronger revenue traction or a more attractive entry price before I would commit fresh capital. I would watch the next few quarters to see if profit growth can be sustained alongside sales recovery. For now, I'd rather be patient and wait for a margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer